samedan logo
home > news > detailed info

Recipharm Invests in its Single Dose Nasal Platform Capabilities

Recipharm Pharmaceutical Development AB

Recipharm, a global contract development and manufacturing organisation (CDMO), has announced that it is expanding its capabilities for its proprietary Unidose® Xtra (single dose) nasal delivery platform.

Offering advantages over standard systemic delivery systems, Recipharm has seen interest in intranasal drug delivery in pharmaceutical R&D increase significantly over the last 10 years. The potential benefits of nasal delivery include offering a more favourable patient experience, with targeted delivery resulting in a faster response to the medication.

Recipharm has already invested in several of its sites in the UK and US to expand its capabilities for the Unidose® Xtra delivery platform and the following services are now available:
  • Development of Unidose® Xtra prototypes
  • Filling and assembly capabilities to support pre-clinical evaluations
  • System performance testing with regards spray characteristics

The following services using performance-ready components will be offered:
  • Full method development
  • Formulation and Container Closure System (CCS) screening/characterisation
  • GLP material manufacturing and supply
  • Development stability testing

A feasibility study package will also be available. Furthermore, Recipharm’s new GMP suite is being built in North Carolina to support clinical manufacturing.

Joe Neale, Head of Innovation, Development and Programme Management at Recipharm said: “Our customers and therefore patients can benefit from Recipharm’s superior product, and we are proud to be creating a benchmark for ‘real world nasal drug delivery performance’. Our ability to offer drug formulation specific tailoring provides a competitive advantage.”
Print this page
Send to a friend
News and Press Releases

Loftware and Epson Announce Partnership to Revolutionize Labeling Workflows

Portsmouth, NH – 12 April, 2023 – Loftware, the world’s largest cloud-based Enterprise Labeling and Artwork Management provider, and Seiko Epson Corporation (TSE: 6724, “Epson”), the global leader in color label printers, today announced a strategic partnership that aims to revolutionize customers’ labeling workflows.
More info >>

White Papers

Bio/Pharmaceutical Methods: Do your Analytical Methods Hold Up to Regulatory Scrutiny?

Eurofins BioPharma Product Testing

As FDA guidelines evolve and drug products on the market begin to age, bio/pharmaceutical manufacturers face scrutiny of the original methods used to support these products. Therefore, manufacturers must re-evaluate these methods to ensure they comply with current FDA expectations. Some manufacturers are even facing consent decrees imposed by the agency requiring them to bring methods up to current standards within a specified timeframe. This exercise requires significant amounts of time and resources, which many manufacturers do not have since they are focused on getting their next products to market. For that reason, some clients have been turning to Eurofins Lancaster Laboratories for support.
More info >>

Industry Events

The Pharmaceutical Manufacturing and Packaging Congress 2023 (PHARMAP 2023)

12-13 June 2023, Hilton Geneva Hotel & Conference Centre, Geneva, Switzerland

The Pharmaceutical Manufacturing and Packaging Congress 2023 (PHARMAP 2023) gathers top-level management from pharmaceutical companies of manufacturing, primary and secondary packaging, purchasing, and supply chain and procurement sectors, CMOs and CDMOs leaders, heads from government and institution on 12-13, June, 2023 in Geneva, Switzerland.
More info >>

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement